NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma - Wikidata - wikimedia - TriplyDB

NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma

NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma

http://www.wikidata.org/entity/Q35992165

about

Potential for immunotherapy in soft tissue sarcoma Prospects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderly Current Immunotherapies for Sarcoma: Clinical Trials and Rationale T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma.NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target.Cancer-testis antigens PRAME and NY-ESO-1 correlate with tumour grade and poor prognosis in myxoid liposarcoma.Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation.Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma.New targets for the immunotherapy of colon cancer-does reactive disease hold the answer?Novel systemic therapies in advanced liposarcoma: a review of recent clinical trial results Current management options for liposarcoma and challenges for the future.Sarcoma immunotherapy: past approaches and future directions.Adoptive immunotherapy against sarcomas.New York esophageal squamous cell carcinoma-1 and cancer immunotherapy.Histology-Driven Therapy: The Importance of Diagnostic Accuracy in Guiding Systemic Therapy of Soft Tissue Tumors.Metastatic soft tissue sarcoma: current treatment landscape and future perspectives.Cancer testis antigen and immunotherapy.Cancer/Testis Antigens: Expression, Regulation, Tumor Invasion, and Use in Immunotherapy of Cancers.Pharmacological therapies for Liposarcoma.Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations.Analysis of the intratumoral adaptive immune response in well differentiated and dedifferentiated retroperitoneal liposarcoma.Detection of cancer/testis antigens as a diagnostic tool in routine pathology practice.The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients.Clinical and Molecular Spectrum of Liposarcoma.Understanding sarcomas and other rare tumors: an interview with Robin L Jones.Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms.Soft tissue sarcomas: From a morphological to a molecular biological approach.NY-ESO-1 (CTAG1B) expression in mesenchymal tumors.NY-ESO-1 Based Immunotherapy of Cancer: Current Perspectives.Sarcoma-The standard-bearer in cancer discovery.Cytokine Induced Killer cells are effective against sarcoma cancer stem cells spared by chemotherapy and target therapy Addressing the Adult Soft Tissue Sarcoma Microenvironment with Intratumoral Immunotherapy Making progress in a rare disease: emerging therapeutics in soft tissue sarcomas

P2860

Q27008830-895AE6AB-82DB-4D83-BFE6-375427B2DE29 Q27025344-D4D57F63-1D40-441F-9A45-9439F356709E Q28067036-AC960B9A-2923-4105-8668-6BE161C21E17 Q30491565-0C47EA70-F7CF-4C5A-95A2-BE9644011C42 Q30591778-CDCC3FDB-B7DC-45C5-A553-74D0ABE15F46 Q34870799-184A717F-4D60-4B49-9BDE-837E9EB32E0B Q36456502-4EF053C2-E54D-474F-8995-7390F2634B8C Q37082518-5FF02C9C-AD65-45A6-A8A6-FCD96433D887 Q37136357-FEF1B9B6-4FCA-4A28-8582-30CEFED7B97B Q37687307-6037AD38-B3EC-4375-AEE7-B1C40D9CA931 Q38089480-94395712-86E5-4EE1-9D7C-F9ABEFF038BB Q38161734-6C3F6090-94FC-450A-A3F3-3F1169DD6770 Q38176387-F3C5083B-CA09-4223-838B-FB7DD8024329 Q38207986-72822891-934E-473D-87D5-B9475754900C Q38291193-161193B9-2A29-4360-9DA1-A824EE46A159 Q38445350-B8AD2C84-DD35-4E18-939B-DE4A3F6E4F9B Q38591828-1F2A9B9E-4E1B-4B51-8F57-AF264EDE8D44 Q38692839-4512D559-99C9-4F05-82AA-3CB9FABA92B5 Q38912232-AD8C210A-CF38-454F-ABDE-EEB77F0A8C1C Q38948541-1D8512C7-36B3-4306-B9C1-FBAFA9F74963 Q38991731-1C8D1DD5-BD5C-44BF-890A-0AC830F4F403 Q41105379-8D4B26E8-81E6-4DA0-B398-BBF3D728B762 Q41370229-F1A93708-33B1-4A85-81AE-32FA1070BE6B Q41768311-6F4D5692-741B-4F24-A72B-14C9F76D93FC Q47244891-7970D110-2D7D-49B6-AD2B-875296549577 Q47315579-211908F1-0C5B-4C45-B73C-00A83F77ADA7 Q47379238-E76B716B-CB7B-4CB8-A456-2BA522F9F872 Q47936113-C45A4F2D-83BD-4A5D-83DE-8D0EFED51390 Q51061495-8FD88A86-9B67-447B-80CC-D190E96AC090 Q51817033-3A44EA3D-EA78-4EB9-9260-B9DFB1BCF63D Q53081281-29DF14C7-1B1F-4FA3-8D00-072D87BE0C07 Q54945263-11BE306A-8CFA-4E72-826B-2DD2A2B45F7F Q55379483-116A573F-E85E-45ED-ADE5-3A05C7520D9E Q58566155-5680396B-4199-4E7E-B214-EA24F65CDF43 Q58787920-00865F7F-375C-4BC6-834B-90161D985069 Q59133043-6DF5316A-8121-4C1C-A97C-AECA5400F60C

P2860

NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma

http://www.wikidata.org/entity/Q35992165

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

NY-ESO-1 is a ubiquitous immun ...... myxoid/round cell liposarcoma

@ast

NY-ESO-1 is a ubiquitous immun ...... myxoid/round cell liposarcoma

@en

type

label

NY-ESO-1 is a ubiquitous immun ...... myxoid/round cell liposarcoma

@ast

NY-ESO-1 is a ubiquitous immun ...... myxoid/round cell liposarcoma

@en

prefLabel

NY-ESO-1 is a ubiquitous immun ...... myxoid/round cell liposarcoma

@ast

NY-ESO-1 is a ubiquitous immun ...... myxoid/round cell liposarcoma

@en

P1433

Q35992165-849CE09C-4C81-4940-8CA9-CB6B6EA24BB8

P1476

Q35992165-4CD4D84D-3E79-4614-95C0-16FDEEF08B07

P2093

Q35992165-20F270F6-D5BD-4417-B912-E3D84686F661

Q35992165-2D4F4E77-7EB1-4AB9-9496-CD2B25427201

Q35992165-331905F3-4F1A-4AED-9AD2-A003DCB5522A

Q35992165-3478EAE8-887D-448A-9CA9-06FDCBBE5C3A

Q35992165-49ED1362-B6DE-4C06-A8FD-D25B20C8FFC4

Q35992165-51E0F359-9402-4490-84F7-C1A3D9C773E7

Q35992165-6F42265F-FA78-47F9-ADFD-5BEBB71AAC17

Q35992165-738B0611-17B7-4D34-9DFD-445C2CD73F2D

Q35992165-7D4F3120-54B6-4770-9CDF-79F9C2283F5E

Q35992165-A8AC5F3A-75EB-4132-B5B0-E57F1227AECB

P2860

Q35992165-004D18D7-2295-484C-B9C9-A90EB1785D36

Q35992165-039C6897-872B-4C24-BC1A-E3285E29BA86

Q35992165-0C663E13-F58F-401E-9238-EDBFA484C83E

Q35992165-0E1D17E6-872C-40A7-93FA-3DF4BE0B11A0

Q35992165-0EAD2740-9CE9-436B-8172-A4BE350E6B1F

Q35992165-17DB33C6-22EC-4365-85B5-DACA88DA06F8

Q35992165-3DD444B8-59E5-4506-B32C-48BEA5E399C6

Q35992165-46462E61-A703-4A01-9E6F-822C0EADBBEA

Q35992165-49F93D2A-18D9-4B96-AC8B-787C3B1EC2C9

Q35992165-4DD4A19C-1640-4B29-8110-820AA14F8164

P304

Q35992165-F6B01B23-B2BE-4C99-B203-A45876D483D8

P31

Q35992165-5E29838F-AF25-4B1B-A1A0-5A21463B30FA

P356

Q35992165-19B33E6C-73DB-4100-A6D6-CF4D794BC01A

P407

Q35992165-CA1F74E6-50F4-4348-939C-DF7E70F81D5D

P433

Q35992165-39DECC8C-EC0A-43E7-8D7A-427A7FD1217C

P478

Q35992165-051C8FF5-F359-48D6-9024-760C79DE36D0

P577

Q35992165-C76DD438-5715-408A-9F50-0B54EED4A2D3

P5875

Q35992165-62A1EE80-F574-4BA3-81C8-5D6CBF0D9CEE

P698

Q35992165-1695BF17-FB34-40BB-944E-A890B6955E0D

P921

Q35992165-C762BE31-48B9-422F-8B07-DFB7015B079E

P932

Q35992165-12D288F4-C5DC-4158-9BA7-43C7A5A35E79

P356

P1433

P1476

NY-ESO-1 is a ubiquitous immun ...... myxoid/round cell liposarcoma

@en

P2093

Achim A Jungbluth

http://www.w3.org/2001/XMLSchema#string

Benjamin L Hoch

http://www.w3.org/2001/XMLSchema#string

Cassian Yee

http://www.w3.org/2001/XMLSchema#string

David J Schneider

http://www.w3.org/2001/XMLSchema#string

Elizabeth T Loggers

http://www.w3.org/2001/XMLSchema#string

Erik A Farrar

http://www.w3.org/2001/XMLSchema#string

Ernest U Conrad

http://www.w3.org/2001/XMLSchema#string

Eve Rodler

http://www.w3.org/2001/XMLSchema#string

Janet F Eary

http://www.w3.org/2001/XMLSchema#string

Marie Bleakley

http://www.w3.org/2001/XMLSchema#string

P2860

Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours

Fusion of CHOP to a novel RNA-binding protein in human myxoid liposarcoma

A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma

Immunomic analysis of human sarcoma

A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1

Molecular analysis of the fusion of EWS to an orphan nuclear receptor gene in extraskeletal myxoid chondrosarcoma

Rearrangement of the transcription factor gene CHOP in myxoid liposarcomas with t(12;16)(q13;p11)

Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues

Characterization of the CHOP breakpoints and fusion transcripts in myxoid liposarcomas with the 12;16 translocation

P304

4564-4570

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.27446

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P577

2012-02-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221855759

http://www.w3.org/2001/XMLSchema#string

P698

22359263

http://www.w3.org/2001/XMLSchema#string

P921

P932

3361576

http://www.w3.org/2001/XMLSchema#string